Abstract:Accurate diagnosis of the initial phase of Alzheimer's disease (AD) is essential and crucial. The objective of this research was to employ efficient biomarkers for the diagnostic analysis and classification of AD based on combining structural MRI (sMRI) and resting-state functional MRI (rs-fMRI). So far, several anatomical MRI imaging markers for AD diagnosis have been identified. The use of cortical and subcortical volumes, the hippocampus, and amygdala volume, as well as genetic patterns, has proven to be beneficial in distinguishing patients with AD from the healthy population. The fMRI time series data have the potential for specific numerical information as well as dynamic temporal information. Voxel and graphical analyses have gained popularity for analyzing neurodegenerative diseases, such as Alzheimer's and its prodromal phase, mild cognitive impairment (MCI). So far, these approaches have been utilized separately for the diagnosis of AD. In recent studies, the classification of cases of MCI into those that are not converted for a certain period as stable MCI (MCIs) and those that converted to AD as MCIc has been less commonly reported with inconsistent results. In this study, we verified and validated the potency of a proposed diagnostic framework to identify AD and differentiate MCIs from MCIc by utilizing the efficient biomarkers obtained from sMRI, along with functional brain networks of the frequency range .01-.027 at the resting state and the voxel-based features. The latter mainly included default mode networks (amplitude of low-frequency fluctuation [ALFF], fractional ALFF [ALFF], and regional homogeneity [ReHo]), degree centrality (DC), and salience networks (SN). Pearson's correlation coefficient for measuring fMRI functional networks has proven to be an efficient means for disease diagnosis. We applied the graph theory to calculate nodal features (nodal degree [ND], nodal path length [NL], and between centrality [BC]) as a graphical feature and analyzed the connectivity link between different brain regions. We extracted three-dimensional (3D) patterns to calculate regional coherence and then implement a univariate statistical t-test to access a 3D mask that preserves voxels showing significant changes. Similarly, from sMRI, we calculated the hippocampal subfield and amygdala nuclei volume using Freesurfer (version 6). Finally, we implemented and compared the different feature selection algorithms to integrate the structural features, brain networks, and voxel features to optimize the diagnostic identifications of AD using support vector machine (SVM) classifiers. We also compared the performance of SVM with Random Forest (RF) classifiers. The obtained results demonstrated the potency of our framework, wherein a combination of the hippocampal subfield, the amygdala volume, and brain networks with multiple measures of rs-fMRI could significantly enhance the accuracy of other approaches in diagnosing AD. The accuracy obtained by the proposed method was reported for binary classification. More importantly, the classification results of the less commonly reported MCIs vs. MCIc improved significantly. However, this research involved only the AD Neuroimaging Initiative (ADNI) cohort to focus on the diagnosis of AD advancement by integrating sMRI and fMRI. Hence, the study's primary disadvantage is its small sample size. In this case, the dataset we utilized did not fully reflect the whole population. As a result, we cannot guarantee that our findings will be applicable to other populations.

Multimodal Mri Neuroimaging Biomarkers For Cognitive Normal Adults, Amnesticmild Cognitive Impairment, And Alzheimer'S Disease

Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment

Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment

A Novel Multimodal MRI Analysis for Alzheimer's Disease Based on Convolutional Neural Network

Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers

Application of multimodal MR imaging on studying Alzheimer's disease: a survey

Can Multi-Modal Neuroimaging Evidence from Hippocampus Provide Biomarkers for the Progression of Amnestic Mild Cognitive Impairment?

Evaluation of Functional Mri Markers in Mild Cognitive Impairment

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer’s disease: a systematic review

Multimodality Neuroimaging in Mild Cognitive Impairment: A Cross-sectional Comparison Study

Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques

A Multimodal Structural and Functional Neuroimaging Study of Amnestic Mild Cognitive Impairment

Aberrant Connectivity in Mild Cognitive Impairment and Alzheimer Disease Revealed by Multimodal Neuroimaging Data.

Combining Multimodal Neuroimaging Biomarkers in the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment

Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease

Alzheimer's Disease Diagnosis and Biomarker Analysis Using Resting-State Functional MRI Functional Brain Network With Multi-Measures Features and Hippocampal Subfield and Amygdala Volume of Structural MRI

Cognitive Function Assessment and Prediction for Subjective Cognitive Decline and Mild Cognitive Impairment.

MRI biomarkers for Alzheimer's disease: the impact of functional connectivity in the default mode network and structural connectivity between lobes on diagnostic accuracy

MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations

Detecting conversion from mild cognitive impairment to Alzheimer's disease using FLAIR MRI biomarkers

Distinct Laterality Alterations Distinguish Mild Cognitive Impairment and Alzheimer'S Disease from Healthy Aging: Statistical Parametric Mapping with High Resolution Mri